Sun Pharma Delivers Strong Q3 Performance with 15% Net Profit Growth

Sun Pharmaceutical Industries reported robust Q3 FY25 financial results, with net profit rising 15% to Rs 2,903.4 crore. The company's revenue increased 10.5% to Rs 13,675 crore, driven by strong domestic formulation sales, which grew 14% to Rs 4,300 crore. The company maintained its market leadership in India, with market share increasing from 7.8% to 8.2%. 
Sun Pharma also declared an interim dividend of Rs 10.5 per share.

Key Highlights:
- India formulation sales: 14% YoY growth
- Global specialty sales: 17.5% jump
- Emerging markets sales: 10% increase
- R&D investments: Rs 845 crore (6.3% of sales)
Source: Moneycontrol, Economic Times, Business Standard